dc.contributor.author | Vasudev, NS | |
dc.contributor.author | Selby, PJ | |
dc.contributor.author | Banks, RE | |
dc.date.accessioned | 2018-08-08T09:15:19Z | |
dc.date.issued | 2012-09-27 | |
dc.identifier.citation | BMC MEDICINE, 2012, 10 | |
dc.identifier.issn | 1741-7015 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/2294 | |
dc.identifier.doi | 10.1186/1741-7015-10-112 | |
dc.description.abstract | Significant advances in our understanding of the biology of renal cell carcinoma (RCC) have been achieved in recent years. These insights have led to the introduction of novel targeted therapies, revolutionising the management of patients with advanced disease. Nevertheless, there are still no biomarkers in routine clinical use in RCC. Tools used routinely to determine prognosis have not changed over the past decade; classification remains largely morphology based; and patients continue to be exposed to potentially toxic therapy with no indication of the likelihood of response. Thus the need for biomarkers in RCC is urgent. Here, we focus on recent advances in our understanding of the genetics and epigenetics of RCC, and the potential for such knowledge to provide novel markers and therapeutic targets. We highlight on-going research that is likely to deliver further candidate markers as well as generating large, well-annotated sample banks that will facilitate future studies. It is imperative that promising candidates are validated using these resources, and in subsequent prospective clinical trials, so that future biomarkers may be used in the clinic to personalize patient care. | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | BIOMED CENTRAL LTD | |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0 | |
dc.title | Renal cancer biomarkers: the promise of personalized care | |
dc.type | Journal Article | |
rioxxterms.versionofrecord | 10.1186/1741-7015-10-112 | |
rioxxterms.licenseref.uri | https://creativecommons.org/licenses/by/4.0 | |
rioxxterms.licenseref.startdate | 2012-09-27 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | BMC MEDICINE | |
pubs.notes | affiliation: Vasudev, NS (Reprint Author), Inst Canc Res, Fulham Rd, London SW3 6JB, England. Vasudev, Naveen S., Inst Canc Res, London SW3 6JB, England. Selby, Peter J.; Banks, Rosamonde E., St James Univ Hosp, Canc Res UK Ctr, Leeds Inst Mol Med, Leeds, W Yorkshire, England. article-number: 112 keywords: Biomarkers; epigenomics; genomics; renal cell carcinoma; transcriptomics keywords-plus: GENOME-WIDE ASSOCIATION; CPG ISLAND METHYLATION; CELL CARCINOMA; BLADDER-CANCER; KIDNEY CANCER; IDENTIFICATION; GENES; EXPRESSION; SUNITINIB; MARKERS research-areas: General & Internal Medicine web-of-science-categories: Medicine, General & Internal author-email: [email protected] orcid-numbers: Banks, Rosamonde/0000-0002-0042-8715 number-of-cited-references: 61 times-cited: 33 usage-count-last-180-days: 0 usage-count-since-2013: 8 journal-iso: BMC Med. doc-delivery-number: 055CK unique-id: ISI:000312392600003 oa: gold da: 2018-08-08 | |
pubs.notes | No embargo | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Closed research teams | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Closed research teams/Tumour Biology | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Closed research teams | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Closed research teams/Tumour Biology | |
pubs.volume | 10 | |
pubs.embargo.terms | No embargo | |
icr.researchteam | Tumour Biology | |
dc.contributor.icrauthor | Vasudev, Naveen | |